P22-1 Nivolumab combination chemotherapy (NC) for HER2-negative, unresectable, advanced, or recurrent gastric cancer (AGC): A retrospective observational study

Wakana Chikaishi,Akitaka Makiyama,Itaru Yasufuku, Hiroshi Tsuchiya,Hirokatsu Hayashi,Yuta Sato,Ryuichi Asai, Jesse Yu Tajiama,Chinatsu Makiyama, Shinya Uemura,Takashi Ibuka,Takuji Iwashita,Shigeru Kiyama,Yoshihiro Tanaka,Naoki Okumura,Katsutoshi Murase, Takao Takahashi,Masahito Shimizu,Nobuhisa Matsuhashi

Annals of Oncology（2023）

引用 0|浏览9

暂无评分

摘要

In November 2021, first-line treatments available for of HER2-negative, AGC were expanded with the addition of NC. However, there are few reports investigating the efficacy and safety of NC in clinical practice.

查看译文

关键词

recurrent gastric cancer,nivolumab combination chemotherapy,gastric cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要